Semaglutide (GLP-1) (3mg / 5mg / 10mg)

Semaglutide (GLP-1) Peptide

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) analog, containing 30-31 amino acids.

Chemical Makeup

Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight: 4114 g/mol
Other Titles: Glucagon-like peptide-1 (GLP-1)

Semaglutide Research

Research in murine models suggests that Semaglutide may interact with GLP-1 receptors. The GLP-1 receptors are G-protein-coupled receptors (GPCRs). Their activation may lead to the exchange of GDP for GTP on the G-protein, triggering a signaling pathway that involves the enzyme adenylyl cyclase. Adenylyl cyclase may then convert ATP to cyclic AMP (cAMP), which in turn may activate protein kinase A (PKA). PKA might phosphorylate various proteins, leading to several cellular actions. Semaglutide might also activate the GLP-1 receptor-mediated phosphoinositide 3-kinase (PI3K) pathway. This pathway might produce phosphatidylinositol 3,4,5-trisphosphate (PIP3), activating protein kinase B (Akt).

Additionally, Semaglutide may recruit beta-arrestins to the GLP-1 receptor. When beta-arrestins bind to the receptor, they might facilitate receptor desensitization and internalization. This internalization might involve clathrin-coated pits forming vesicles transporting the receptor to be degraded or recycled. Beta-arrestins might also initiate alternative signaling pathways, such as the MAPK pathway. An experiment conducted on murine models presented with a GLP-1 agonist similar to Semaglutide, in combination with lisofylline, suggested that the peptide might promote the growth of pancreatic beta cells and prevent cellular apoptosis.

Semaglutide peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

Not for human consumption.

References:

1. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155. doi: 10.3389/fendo.2019.00155. PMID: 31031702; PMCID: PMC6474072. https://pubmed.ncbi.nlm.nih.gov/31031702/
2. Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising antiobesity drug. Obes Rev. 2019 Jun;20(6):805-815. doi: 10.1111/obr.12839. Epub 2019 Feb 15. PMID: 30768766. https://pubmed.ncbi.nlm.nih.gov/30768766/
3. National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 56843331, Semaglutide.
4. Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021). GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Frontiers in endocrinology, 12, 721135. https://doi.org/10.3389/fendo.2021.721135
5. Hager, M. V., Johnson, L. M., Wootten, D., Sexton, P. M., & Gellman, S. H. (2016). β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues. Journal of the American Chemical Society, 138(45), 14970–14979. https://doi.org/10.1021/jacs.6b08323
6. Tipa, R. O., Balan, D. G., Georgescu, M. T., Ignat, L. A., Vacaroiu, I. A., Georgescu, D. E., Raducu, L., Mihai, D. A., Chiperi, L. V., & Balcangiu-Stroescu, A. E. (2024). A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies. International journal of molecular sciences, 25(9), 4972. https://doi.org/10.3390/ijms25094972